23.02 USD
-1.21 (-4.99%)
23.08 USD
+0.06 (+0.26%)
We assign a fundamental rating of 5 out of 10 to GLUE. GLUE was compared to 525 industry peers in the Biotechnology industry. GLUE has an excellent financial health rating, but there are some minor concerns on its profitability. GLUE has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- In the past year GLUE was profitable.
- In the past year GLUE had a positive cash flow from operations.
- In the past 5 years GLUE always reported negative net income.
- In the past 5 years GLUE reported 4 times negative operating cash flow.
1.2 Ratios
- GLUE has a Return On Assets of 4.56%. This is amongst the best in the industry. GLUE outperforms 91.05% of its industry peers.
- GLUE's Return On Equity of 8.52% is amongst the best of the industry. GLUE outperforms 92.00% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 1.69%, GLUE belongs to the top of the industry, outperforming 89.52% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.56% | ||
| ROE | 8.52% | ||
| ROIC | 1.69% |
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin of GLUE (11.54%) is better than 91.62% of its industry peers.
- GLUE has a better Operating Margin (4.69%) than 89.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 4.69% | ||
| PM (TTM) | 11.54% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), GLUE is destroying value.
- The number of shares outstanding for GLUE has been increased compared to 1 year ago.
- The number of shares outstanding for GLUE has been increased compared to 5 years ago.
- GLUE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- GLUE has an Altman-Z score of 4.46. This indicates that GLUE is financially healthy and has little risk of bankruptcy at the moment.
- GLUE has a better Altman-Z score (4.46) than 72.00% of its industry peers.
- There is no outstanding debt for GLUE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.46 |
ROIC/WACC0.19
WACC8.9%
2.3 Liquidity
- GLUE has a Current Ratio of 6.54. This indicates that GLUE is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of GLUE (6.54) is better than 66.86% of its industry peers.
- GLUE has a Quick Ratio of 6.54. This indicates that GLUE is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 6.54, GLUE is in the better half of the industry, outperforming 67.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.54 | ||
| Quick Ratio | 6.54 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 116.94% over the past year.
- GLUE shows a strong growth in Revenue. In the last year, the Revenue has grown by 1112.27%.
EPS 1Y (TTM)116.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.79%
Revenue 1Y (TTM)1112.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%38.54%
3.2 Future
- GLUE is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -9.22% yearly.
- GLUE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.59% yearly.
EPS Next Y72.28%
EPS Next 2Y-18.02%
EPS Next 3Y-10.72%
EPS Next 5Y-9.22%
Revenue Next Year431.8%
Revenue Next 2Y47.38%
Revenue Next 3Y36.35%
Revenue Next 5Y22.59%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 74.26, GLUE can be considered very expensive at the moment.
- Based on the Price/Earnings ratio, GLUE is valued cheaply inside the industry as 90.10% of the companies are valued more expensively.
- GLUE is valuated expensively when we compare the Price/Earnings ratio to 27.32, which is the current average of the S&P500 Index.
- GLUE is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 74.26 | ||
| Fwd PE | N/A |
4.2 Price Multiples
- GLUE's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GLUE is cheaper than 90.67% of the companies in the same industry.
- Based on the Price/Free Cash Flow ratio, GLUE is valued cheaper than 98.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 10.34 | ||
| EV/EBITDA | 59.6 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- GLUE's earnings are expected to decrease with -10.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)1.03
PEG (5Y)N/A
EPS Next 2Y-18.02%
EPS Next 3Y-10.72%
5. Dividend
5.1 Amount
- No dividends for GLUE!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
23.02
-1.21 (-4.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-18 2026-03-18/amc
Inst Owners105.54%
Inst Owner Change0.08%
Ins Owners0.81%
Ins Owner Change1.5%
Market Cap1.50B
Revenue(TTM)181.54M
Net Income(TTM)20.95M
Analysts85.33
Price Target28.49 (23.76%)
Short Float %13.09%
Short Ratio5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)37.53%
Min EPS beat(2)13.2%
Max EPS beat(2)61.87%
EPS beat(4)4
Avg EPS beat(4)354.59%
Min EPS beat(4)13.2%
Max EPS beat(4)1080.39%
EPS beat(8)7
Avg EPS beat(8)177.66%
EPS beat(12)11
Avg EPS beat(12)119.51%
EPS beat(16)13
Avg EPS beat(16)84.82%
Revenue beat(2)2
Avg Revenue beat(2)120.76%
Min Revenue beat(2)110.55%
Max Revenue beat(2)130.97%
Revenue beat(4)4
Avg Revenue beat(4)277.19%
Min Revenue beat(4)110.55%
Max Revenue beat(4)444.91%
Revenue beat(8)6
Avg Revenue beat(8)183.66%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)60.25%
PT rev (3m)67.09%
EPS NQ rev (1m)-3.45%
EPS NQ rev (3m)-116.69%
EPS NY rev (1m)2.92%
EPS NY rev (3m)-43.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-40.54%
Revenue NY rev (1m)1.38%
Revenue NY rev (3m)3.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 74.26 | ||
| Fwd PE | N/A | ||
| P/S | 8.26 | ||
| P/FCF | 10.34 | ||
| P/OCF | 10.05 | ||
| P/B | 6.1 | ||
| P/tB | 6.1 | ||
| EV/EBITDA | 59.6 |
EPS(TTM)0.31
EY1.35%
EPS(NY)-1.42
Fwd EYN/A
FCF(TTM)2.23
FCFY9.67%
OCF(TTM)2.29
OCFY9.95%
SpS2.79
BVpS3.78
TBVpS3.78
PEG (NY)1.03
PEG (5Y)N/A
Graham Number5.13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.56% | ||
| ROE | 8.52% | ||
| ROCE | 2.14% | ||
| ROIC | 1.69% | ||
| ROICexc | 94.17% | ||
| ROICexgc | 94.17% | ||
| OM | 4.69% | ||
| PM (TTM) | 11.54% | ||
| GM | N/A | ||
| FCFM | 79.89% |
ROA(3y)-30.94%
ROA(5y)-37.13%
ROE(3y)-49.37%
ROE(5y)-71.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 49.42% | ||
| Cap/Sales | 2.27% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 885.62% | ||
| Profit Quality | 692.36% | ||
| Current Ratio | 6.54 | ||
| Quick Ratio | 6.54 | ||
| Altman-Z | 4.46 |
F-Score8
WACC8.9%
ROIC/WACC0.19
Cap/Depr(3y)233.13%
Cap/Depr(5y)356.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)116.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.79%
EPS Next Y72.28%
EPS Next 2Y-18.02%
EPS Next 3Y-10.72%
EPS Next 5Y-9.22%
Revenue 1Y (TTM)1112.27%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%38.54%
Revenue Next Year431.8%
Revenue Next 2Y47.38%
Revenue Next 3Y36.35%
Revenue Next 5Y22.59%
EBIT growth 1Y106.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.16%
EBIT Next 3Y42.19%
EBIT Next 5YN/A
FCF growth 1Y218.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y253.12%
OCF growth 3YN/A
OCF growth 5YN/A
MONTE ROSA THERAPEUTICS INC / GLUE FAQ
Can you provide the ChartMill fundamental rating for MONTE ROSA THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 5 / 10 to GLUE.
What is the valuation status of MONTE ROSA THERAPEUTICS INC (GLUE) stock?
ChartMill assigns a valuation rating of 4 / 10 to MONTE ROSA THERAPEUTICS INC (GLUE). This can be considered as Fairly Valued.
What is the profitability of GLUE stock?
MONTE ROSA THERAPEUTICS INC (GLUE) has a profitability rating of 4 / 10.
Can you provide the PE and PB ratios for GLUE stock?
The Price/Earnings (PE) ratio for MONTE ROSA THERAPEUTICS INC (GLUE) is 74.26 and the Price/Book (PB) ratio is 6.1.
Can you provide the financial health for GLUE stock?
The financial health rating of MONTE ROSA THERAPEUTICS INC (GLUE) is 8 / 10.